Literature DB >> 24028925

The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia.

Yaroslau Compta1, Laura Parkkinen, Peter Kempster, Mariana Selikhova, Tammaryn Lashley, Janice L Holton, Andrew J Lees, Tamas Revesz.   

Abstract

BACKGROUND: Dementia is one of the milestones of advanced Parkinson's disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications.
OBJECTIVE: The aim of this study was to review the relative importance of Lewy-related α-synuclein and Alzheimer's tau and amyloid-β (Aβ) pathologies in disease progression and dementia in PD.
METHODS: We reviewed studies conducted at the Queen Square Brain Bank, Institute of Neurology, University College London, using large PD cohorts.
RESULTS: Cortical Lewy- and Alzheimer-type pathologies are associated with milestones of poorer prognosis and with non-tremor predominance, which have been, in turn, linked to dementia. The combination of these pathologies is the most robust neuropathological substrate of PD-related dementia, with cortical Aβ burden determining a faster progression to dementia.
CONCLUSION: The shared relevance of these pathologies in PD progression and dementia is in line with experimental data suggesting synergism between α-synuclein, tau and Aβ and with studies testing these proteins as disease biomarkers, hence favouring the eventual testing of therapeutic strategies targeting these proteins in PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24028925      PMCID: PMC4194631          DOI: 10.1159/000354670

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  27 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

2.  CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

Authors:  A Siderowf; S X Xie; H Hurtig; D Weintraub; J Duda; A Chen-Plotkin; L M Shaw; V Van Deerlin; J Q Trojanowski; C Clark
Journal:  Neurology       Date:  2010-08-18       Impact factor: 9.910

3.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Authors:  Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

4.  A clinico-pathological study of subtypes in Parkinson's disease.

Authors:  M Selikhova; D R Williams; P A Kempster; J L Holton; T Revesz; A J Lees
Journal:  Brain       Date:  2009-09-16       Impact factor: 13.501

5.  β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia.

Authors:  Martijn L T M Müller; Kirk A Frey; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Roger L Albin; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2012-12-12       Impact factor: 10.338

6.  Distinct α-synuclein strains differentially promote tau inclusions in neurons.

Authors:  Jing L Guo; Dustin J Covell; Joshua P Daniels; Michiyo Iba; Anna Stieber; Bin Zhang; Dawn M Riddle; Linda K Kwong; Yan Xu; John Q Trojanowski; Virginia M Y Lee
Journal:  Cell       Date:  2013-07-03       Impact factor: 41.582

7.  β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy.

Authors:  Hitoshi Shimada; Hitoshi Shinotoh; Shigeki Hirano; Michie Miyoshi; Koichi Sato; Noriko Tanaka; Tsuneyoshi Ota; Kiyoshi Fukushi; Toshiaki Irie; Hiroshi Ito; Makoto Higuchi; Satoshi Kuwabara; Tetsuya Suhara
Journal:  Mov Disord       Date:  2012-12-05       Impact factor: 10.338

Review 8.  CSF markers for incipient Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

9.  Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study.

Authors:  Yaroslau Compta; Joana B Pereira; Jose Ríos; Naroa Ibarretxe-Bilbao; Carme Junqué; Núria Bargalló; Ana Cámara; Mariateresa Buongiorno; Manel Fernández; Claustre Pont-Sunyer; Maria J Martí
Journal:  Parkinsonism Relat Disord       Date:  2013-05-03       Impact factor: 4.891

Review 10.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

View more
  31 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

Review 2.  Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Kirk A Frey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-14       Impact factor: 5.081

3.  Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.

Authors:  David G Coughlin; Helen Petrovitch; Lon R White; Joseph Noorigian; Kamal H Masaki; G Webster Ross; John E Duda
Journal:  Parkinsonism Relat Disord       Date:  2019-03-28       Impact factor: 4.891

4.  Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.

Authors:  Ragnhild E Skogseth; Kolbjorn Bronnick; Joana B Pereira; Brit Mollenhauer; Daniel Weintraub; Tormod Fladby; Dag Aarsland
Journal:  J Parkinsons Dis       Date:  2015       Impact factor: 5.568

5.  A possible relationship between telomere length and markers of neurodegeneration in rat brain after welding fume inhalation exposure.

Authors:  Mohammad Shoeb; Gul M Mustafa; Vamsi K Kodali; Kelly Smith; Katherine A Roach; Gregory Boyce; Terence Meighan; Jenny R Roberts; Aaron Erdely; James M Antonini
Journal:  Environ Res       Date:  2019-11-05       Impact factor: 6.498

Review 6.  Amyloid-β and Parkinson's disease.

Authors:  Ee Wei Lim; Dag Aarsland; Dominic Ffytche; Raquel Natalia Taddei; Daniel J van Wamelen; Yi-Min Wan; Eng King Tan; Kallol Ray Chaudhuri
Journal:  J Neurol       Date:  2018-10-30       Impact factor: 4.849

7.  Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model.

Authors:  Tarek K Motawi; Nermin A H Sadik; Manal A Hamed; Sanaa A Ali; Wagdy K B Khalil; Yomna R Ahmed
Journal:  Mol Cell Biochem       Date:  2019-12-09       Impact factor: 3.396

8.  Local cortical overexpression of human wild-type alpha-synuclein leads to increased dendritic spine density in mouse.

Authors:  Lucia M Wagner; Sheyna M Nathwani; Patrick P Ten Eyck; Georgina M Aldridge
Journal:  Neurosci Lett       Date:  2020-05-14       Impact factor: 3.046

Review 9.  Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.

Authors:  David G Coughlin; Howard I Hurtig; David J Irwin
Journal:  Mov Disord       Date:  2019-10-29       Impact factor: 10.338

10.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.

Authors:  Anette Schrag; Uzma Faisal Siddiqui; Zacharias Anastasiou; Daniel Weintraub; Jonathan M Schott
Journal:  Lancet Neurol       Date:  2016-11-18       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.